Why the study?
It remained unclear whether intensive BP lowering has a greater effect on the occurrence and regression of LVH compared to standard BP lowering in patients with hypertension.
Does intensive blood pressure lowering reduce the occurrence and promote regression of left ventricular hypertrophy in patients with hypertension?
Does intensive blood pressure lowering reduce the occurrence and promote regression of left ventricular hypertrophy in patients with hypertension?
Intensive blood pressure lowering significantly reduces the occurrence and promotes the regression of left ventricular hypertrophy in hypertensive patients, particularly those at high cardiovascular risk.
Supports intensive BP lowering to prevent and regress LVH in hypertension; reinforces evidence for structural cardiac benefits.
Background Successful antihypertensive management can limit left ventricular hypertrophy (LVH) and improve the clinical prognosis. However, it remains unclear whether intensive blood pressure (BP) lowering has a greater effect on the occurrence and regression of LVH compared to standard BP lowering.Methods We searched the electronic databases of PubMed, EMBASE and Web of Science from inception to 2 June 2023. Relevant and eligible studies were included. A random-effects model was used to estimate the pooled odds ratio (OR) and 95% confidence intervals (CI).Result Four RCTs including 20,747 patients met our inclusion criteria. The results demonstrated that intensive BP lowering was associated with a significantly lower rate of LVH (OR 0.85; 95%CI: 0.78–0.93; I2 48.6%) in patients with hypertension compared to standard BP lowering. Subgroup analysis revealed that the effect of intensive BP lowering on LVH was more pronounced in patients with high cardiovascular disease (CVD) risk factors (OR 0.82; 95%CI: 0.72–0.93; I2 57.9%). In addition, intensive BP lowering led to significant regression of LVH (OR 0.68; 95%CI: 0.52–0.88; I2 45.5%).Conclusions Our study suggests that intensive BP lowering should be instigated as soon as possible for optimal control of BP and to prevent regression of LVH, especially in patients with high risk of CVD. However, caution is warranted when treating hypertensive patients with LVH to systolic blood pressure (SBP) targets below 130 mm Hg.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: